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A utoimmune hemolytic anemia (AIHA) and immune thrombocytopenia are relatively comm m mon in chronic lymphocytic leukemia (CLL), but the presence of both in the same patient is rare. The combination of AIHA and immune thrombocytopenia is known as Evans syndrome which is an idiopathic dism m order without an underlying cause. 1 Evans syndrome may also develop as a secondary syndrome in associam m tion with a variety of conditions like CLL, systemic lum m pus erythematosus (SLE) and following autologous or allogeneic stem cell transplantation. 2m5 This syndrome can be resistant to a variety of therapeutic measures and associated with significant morbidity and mortality. Rituximab is a monoclonal antibody against CD20 anm m tigen present on Bmlymphocytes. It has shown promise in the treatment of many hematologic and nonmhemam m tologic immunologic disorders. We present the case of a 68myearmold patient with AIHA and immune thromm m bocytopenic purpura (ITP) associated with CLL and discuss the role of rituximab in its management.
Case
A 68myearmold Saudi male presented to the emergency department with dizziness, fatigability, anorexia and undocumented weight loss associated with intermittent fever and sweating of 3 months duration. He also comm m plained of dark colored urine of a few days duration. The severity of symptoms increased 2 weeks prior to presenm m tation. He was known to suffer from bronchial asthma and hypertension, which were well controlled on regular treatment. Physical examination revealed jaundice, palm m lor and generalized lymphadenopathy. The largest lymph nodes measured 2×2 cm in the axilla. He was apyrexial with normal vital signs. Examination of the chest, heart and nervous system was normal. Abdominal examinam m Bone marrow aspiration and biopsy showed hypercelm m lular bone marrow heavily infiltrated with small mature lymphocytes. Erythropoiesis was increased but megam m karyocytes were normal in number. Normal or increased megakaryocytes are very much consistent with ITP, parm m ticularly in a patient with bone marrow infiltrated with CLL, like our patient. Cell markers on the peripheral blood and bone marrow were positive for CD5, CD23, CD19/CD20, weakly positive for surface membrane imm m munoglobulins and negative for CD10, CD79b, CD103 and FMCm7, consistent with Bmcell CLL. The patient was diagnosed as having CLL associated with AIHA and immune thrombocytopenia (secondary Evans synm m drome) on the basis of these findings.
He received blood transfusions and was started on methylprednisolone 100 mg daily. Chlorambucil pulse therapy was started at a dose of 20 mg daily for 7 days. He continued to hemolyze and the platelet count dropped to 18×10 
Discussion
CLL is a common lymphoproliferative disorder and may be associated with immunological disorders like AIHA and ITP. Both of these disorders, particularly AIHA, are common in CLL at presentation or during the course of the disease, but the presence of both at the same time or sequentially is rare. The combination of Coombsmpositive hemolytic anemia (AIHA) and ITP is known as Evans syndrome. This is a rare immunological disorder with an absence of an underlying etiology that was first described by Robert Evans in 1951. 1 Evans syndrome may also develop as a secondary syndrome in association with different diseases like collagen vascular diseases, lymphoproliferative disorders like CLL and multicentric Castleman disease, following autologous or allogeneic stem cell transplantation, or in response to certain chemotherapeutic or biological agents like inm m terleukinm2 therapy. 2m8 The combination of AIHA and ITP in association with other disorders including CLL has been labeled as "secondary Evans syndrome" by varim m ous authors and investigators and is well documented in the literature. 2m4 Evans syndrome appears to be rarer in adults as most of the studies published are from the pediatric age group. 9, 10 There are a few reports in adults, mostly in the form of case reports. 2, 11 Various therapeutic regimens, including corticosteroids, intravenous immunoglobum m lins, splenectomy and immunosuppressants have been used in primary and secondary Evans syndrome. It apm m pears that most of these measures are unsuccessful in refractory cases 4,9m11 and even bone marrow transplantam m tion has been carried out in some of these patients. 12 A survey in North America showed that Evans syndrome is a chronic disorder with significant morbidity and mortality. 10 It has also been shown that one component (AIHA or ITP) of Evans syndrome may respond to treatment while the other component remains refracm m tory to therapeutic measures. 10, 11 Because of the resism m tant nature of this disease and refractoriness to different modalities of treatment, there is a need to develop new forms of therapy with minimal toxicity. 4 Rituximab (Mabthera, F. HoffmanmLa Roche Ltd, Basel, Switzerland) is a chimeric monoclonal antim m body that targets CD20 antigen on B lymphocytes. Mechanisms of action of rituximab are believed to be induction of apoptosis, complementmmediated cell toxm m icity and antibodymdependent cell toxicity. 13 It has effim m cacy against various Bmcell lymphoid malignancies and has become a part of the therapeutic regimens in differm m ent types of nonmHodgkin' s lymphomas and CLL. 14 Because of the action of rituximab on Bmlymphocytes and its ability to reduce antibody production, it seems to have effectiveness in many immune hematological disorders. 15 During the last few years, reports have apm m peared showing the effectiveness of rituximab in many resistant immune hematological disorders, particularly isolated ITP and AIHA as well as in these disorders when associated with CLL. 16m22 Evans syndrome associm m ated with CLL is very rare. Our literature search identim m fied only one such case treated with rituximab. Seipelt et al reported a case of prolymphocytoid transformed BmCLL with Evans syndrome refractory to alkylating agents and purine analogues. The patient was successm m fully treated with rituximab leading to an improvement in platelet count and a drop in lymphocyte count. 3 Our case highlights the use of rituximab in a patient with AIHA and ITP associated with CLL at the time of initial diagnosis. Some patients with CLL who rem m ceive fludarabine may develop ITP or AIHA, 23, 24 hence our hesitation to use this treatment in our patient. Interestingly, CLL patients who develop ITP or AIHA due to fludarabine, may respond to rituximab. 25, 26 In summary, our case and other previously reported cases suggest that rituximab may be an effective therapy in patients with AIHA and ITP (Evan syndrome). It may have the additional benefit of reducing the leukem m mia burden and should be considered in patients resism m tant to conventional treatment. 
